Natalie McCormick

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4381802/publications.pdf

Version: 2024-02-01

471509 477307 1,457 29 17 29 citations h-index g-index papers 29 29 29 2261 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Validity of Diagnostic Codes for Acute Stroke in Administrative Databases: A Systematic Review. PLoS ONE, 2015, 10, e0135834.	2.5	294
2	Validity of Myocardial Infarction Diagnoses in Administrative Databases: A Systematic Review. PLoS ONE, 2014, 9, e92286.	2.5	193
3	Validity of Heart Failure Diagnoses in Administrative Databases: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e104519.	2.5	156
4	COVIDâ€19 Outcomes in Patients With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A US Multicenter, Comparative Cohort Study. Arthritis and Rheumatology, 2021, 73, 914-920.	5.6	117
5	The rising prevalence and incidence of gout in British Columbia, Canada: Population-based trends from 2000 to 2012. Seminars in Arthritis and Rheumatism, 2017, 46, 451-456.	3.4	83
6	Population Impact Attributable to Modifiable Risk Factors for Hyperuricemia. Arthritis and Rheumatology, 2020, 72, 157-165.	5.6	68
7	The role of diet in hyperuricemia and gout. Current Opinion in Rheumatology, 2021, 33, 135-144.	4.3	60
8	Effects of Low-Fat, Mediterranean, or Low-Carbohydrate Weight Loss Diets on Serum Urate and Cardiometabolic Risk Factors: A Secondary Analysis of the Dietary Intervention Randomized Controlled Trial (DIRECT). Diabetes Care, 2020, 43, 2812-2820.	8.6	49
9	Assessing the Causal Relationships Between Insulin Resistance and Hyperuricemia and Gout Using Bidirectional Mendelian Randomization. Arthritis and Rheumatology, 2021, 73, 2096-2104.	5.6	49
10	Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care. Nature Reviews Rheumatology, 2022, 18, 97-111.	8.0	45
11	Estimation of Primary Prevention of Gout in Men Through Modification of Obesity and Other Key Lifestyle Factors. JAMA Network Open, 2020, 3, e2027421.	5.9	37
12	Trends in Gout and Rheumatoid Arthritis Hospitalizations in Canada From 2000 to 2011. Arthritis Care and Research, 2017, 69, 758-762.	3.4	34
13	Effects of Dietary Patterns on Serum Urate: Results From a Randomized Trial of the Effects of Diet on Hypertension. Arthritis and Rheumatology, 2021, 73, 1014-1020.	5.6	33
14	Socioeconomic Predictors of Incident Depression in Systemic Lupus Erythematosus. Arthritis Care and Research, 2018, 70, 104-113.	3.4	28
15	Hydroxychloroquine and Mortality Among Patients With Systemic Lupus Erythematosus in the General Population. Arthritis Care and Research, 2021, 73, 1219-1223.	3.4	23
16	Dietary and Lifestyle-Centered Approach in Gout Care and Prevention. Current Rheumatology Reports, 2021, 23, 51.	4.7	21
17	Adherence to 2020 to 2025 Dietary Guidelines for Americans and the Risk of New-Onset Female Gout. JAMA Internal Medicine, 2022, 182, 254.	5.1	21
18	Risk of gout flares after vaccination: a prospective case cross-over study. Annals of the Rheumatic Diseases, 2019, 78, 1601-1604.	0.9	20

#	Article	IF	CITATIONS
19	Trends of venous thromboembolism risk before and after diagnosis of gout: a general population-based study. Rheumatology, 2020, 59, 1099-1107.	1.9	20
20	Allopurinol Initiation and All-Cause Mortality Among Patients With Gout and Concurrent Chronic Kidney Disease. Annals of Internal Medicine, 2022, 175, 461-470.	3.9	17
21	Hypouricemia and Mortality Risk in the US General Population. Arthritis Care and Research, 2021, 73, 1171-1179.	3.4	14
22	Impact of adiposity on risk of female gout among those genetically predisposed: sex-specific prospective cohort study findings over >32 years. Annals of the Rheumatic Diseases, 2022, 81, 556-563.	0.9	14
23	Heart disease and the risk of allopurinol-associated severe cutaneous adverse reactions: a general population–based cohort study. Cmaj, 2019, 191, E1070-E1077.	2.0	12
24	Canadians' views on the use of routinely collected data in health research: a patient-oriented cross-sectional survey. CMAJ Open, 2019, 7, E203-E209.	2.4	11
25	Excess Productivity Costs of Systemic Lupus Erythematosus, Systemic Sclerosis, and Sjögren's Syndrome: A General Population–Based Study. Arthritis Care and Research, 2019, 71, 142-154.	3.4	11
26	Decomposition Analysis of Spending and Price Trends for Biologic Antirheumatic Drugs in Medicare and Medicaid. Arthritis and Rheumatology, 2020, 72, 234-241.	5.6	9
27	Filling the gaps in SARDs research: collection and linkage of administrative health data and self-reported survey data for a general population-based cohort of individuals with and without diagnoses of systemic autoimmune rheumatic disease (SARDs) from British Columbia, Canada. BMJ Open, 2017, 7, e013977.	1.9	8
28	Prolonged Increases in Public-Payer Spending and Prices After Unapproved Drug Initiative Approval of Colchicine. JAMA Internal Medicine, 2021, 181, 284.	5.1	7
29	Racial Disparities in the Modern Gout Epidemic. Journal of Rheumatology, 2022, 49, 443-446.	2.0	3